Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 5/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9130261 | 0.80 | KCNN4 (0.41) | KCNN4KIF11HDAC3HDAC4HDAC1 | |
| SCHEMBL3249773 | 0.76 | TSHR (0.44) | KCNN4KIF11HDAC3HDAC4HDAC1 | |
| SCHEMBL3246081 | 0.76 | TSHR (0.44) | KCNN4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6170218 | 0.76 | KCNN4 (0.44) | KCNN4KIF11HDAC3HDAC4HDAC1 | |
| SCHEMBL3114470 | 0.76 | HDAC3 (0.45) | KCNN4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1549012 | 0.76 | HDAC3 (0.45) | KCNN4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL11315435 | 0.75 | KCNN4 (0.48) | KCNN4KIF11HDAC3HDAC4HDAC1 | |
| SCHEMBL10879895 | 0.75 | KCNN4 (0.48) | KCNN4KIF11HDAC3HDAC4HDAC1 | |
| SCHEMBL3665471 | 0.73 | HDAC3 (0.47) | KCNN4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3249429 | 0.72 | CYP2D6 (0.40) | KCNN4KIF11HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114276411-B | Solid phase synthesis method of cyclic peptide compound containing trithioether bond | 北京大学深圳研究生院 | 2024-02-09 | — | — | CN | claimed |
| CN-114685608-A | Cyclic peptide compound containing trithioether bond or derivative thereof, and synthetic method and application thereof | 北京大学深圳研究生院 | 2022-07-01 | — | — | CN | claimed |
| CN-114276411-A | Solid phase synthesis method of cyclic peptide compound containing trithioether bond | 北京大学深圳研究生院 | 2022-04-05 | — | — | CN | claimed |
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | claimed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | claimed |
| EP-0641356-B1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO WELLCOME INC (US) | 1998-04-22 | — | — | EP | claimed |
| US-5543406-A | TREATING ANDROGEN RESPONSIVE OR MEDIATED DISEASE | GLAXO WELLCOME, INC. (US) | 1996-08-06 | — | — | US | claimed |
| EP-0641356-A1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO WELLCOME INC. (US) | 1995-03-08 | — | — | EP | claimed |
| WO-1993013124-A1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO INC. (US) | 1993-07-08 | — | — | WO | claimed |
| CN-114276411-B | Solid phase synthesis method of cyclic peptide compound containing trithioether bond | 北京大学深圳研究生院 | 2024-02-09 | — | — | CN | disclosed |
| CN-114685608-B | Cyclic peptide compound containing trithiophene bond or derivative thereof, synthesis method and application thereof | 北京大学深圳研究生院 | 2023-10-20 | — | — | CN | disclosed |
| CN-114685608-A | Cyclic peptide compound containing trithioether bond or derivative thereof, and synthetic method and application thereof | 北京大学深圳研究生院 | 2022-07-01 | — | — | CN | disclosed |
| CN-114276411-A | Solid phase synthesis method of cyclic peptide compound containing trithioether bond | 北京大学深圳研究生院 | 2022-04-05 | — | — | CN | disclosed |
| US-9758513-B2 | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| EP-0641356-A1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO WELLCOME INC. (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5324833-A | Peptide biosynthesis | NOVABIOCHEM AG (CH) | 1994-06-28 | — | — | US | disclosed |
| WO-1993013124-A1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| US-4596869-A | Pyridinyl and pyrimidinyl derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-06-24 | — | — | US | disclosed |
| US-4395411-A | ANTIBIOTICS; BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-07-26 | — | — | US | disclosed |
| US-4267176-A | Amino or acylamino-substituted pyrimidinyl cephalosporanic acid derivatives and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | NFKBIA, IKBKB, RELA | KCNN4 2545/4885KIF11 4426/4885HDAC3 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.